Around 4,500 people living with advanced lung cancer are set to benefit from the new PBS listing of a checkpoint immunotherapy. Nivolumab (Opvido) has been listed on the PBS for locally advanced or metastatic non-small cell lung cancer and advanced (stage IV) clear cell variant renal cell carcinoma. The move to reimburse the drug represents ...
Already a member?
Enter your email to keep reading.